The Minsa reviews the pharmacovigilance and risk management plan for the Johnson & Johnson pharmaceuticals vaccine, Elvia Lau reported.
The director of Pharmacies and Drugs of the Ministry of Health (
Minsa), Elvia Lau, announced that Panama is reviewing the complete file of the
vaccine against
COVID-19 from the pharmaceutical company
Johnson &
Johnson.
"We are reviewing the complete dossier of the
vaccine dossier ... reviewing the minimum that is presented," Lau said.
She explained that within the verification they evaluate the pharmacovigilance and risk management plan "it is the one that gives you the criteria in a coercive way that makes you do what is currently being done with the
AstraZeneca vaccine, with the recommendations you should not apply it to minors of such age”.
Panama has remained in the negotiations to obtain the
Johnson &
Johnson vaccine against
COVID-19, with the aim of vaccinating citizens who reside in remote places, because it requires the application of a single dose, unlike
vaccines from the rest of the pharmaceutical companies such as
Pfizer,
AstraZeneca, and Sputnik V, which require two doses.
The European Medicines Agency (EMA) has approved the
vaccine developed by the Belgian company Janssen, a subsidiary of the American multinational J&J, after investigating that the benefits continue to outweigh the risks. This given the probability of developing blood clots considered "very rare" side effects.